Compare Stocks → Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AIMTNASDAQ:DCPHNASDAQ:ENTANASDAQ:INSMNASDAQ:MDGL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMTAimmune Therapeutics$34.49$34.46$10.09▼$37.00$2.26B1.761.71 million shsN/ADCPHDeciphera Pharmaceuticals$14.72-0.8%$15.70$9.90▼$17.73$1.19B0.39523,282 shs378,846 shsENTAEnanta Pharmaceuticals$14.00-8.9%$14.78$8.08▼$38.30$324.96M0.47245,430 shs190,811 shsINSMInsmed$26.18+0.1%$27.58$17.35▼$32.00$3.88B0.921.52 million shs1.21 million shsMDGLMadrigal Pharmaceuticals$228.34-2.0%$242.43$119.76▼$322.67$4.64B-0.47364,193 shs251,038 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMTAimmune Therapeutics0.00%0.00%0.00%0.00%0.00%DCPHDeciphera Pharmaceuticals-0.81%-5.70%-0.88%+5.98%-3.85%ENTAEnanta Pharmaceuticals-8.85%-15.36%+3.63%+20.48%-62.54%INSMInsmed+0.11%-7.78%+0.15%-7.95%+48.50%MDGLMadrigal Pharmaceuticals-1.99%-6.67%-19.38%+1.89%-21.08%Could Bitcoin Literally FORCE This Crypto To Rocket Up? (Ad)Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMTAimmune TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ADCPHDeciphera Pharmaceuticals3.0043 of 5 stars3.40.00.03.81.41.70.6ENTAEnanta Pharmaceuticals3.6645 of 5 stars3.10.00.04.73.72.50.6INSMInsmed3.9054 of 5 stars4.51.00.04.52.40.00.6MDGLMadrigal Pharmaceuticals4.6907 of 5 stars4.51.00.04.63.34.20.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMTAimmune TherapeuticsN/AN/AN/AN/ADCPHDeciphera Pharmaceuticals2.80Moderate Buy$23.0056.25% UpsideENTAEnanta Pharmaceuticals2.17Hold$19.3338.10% UpsideINSMInsmed3.00Buy$44.6470.50% UpsideMDGLMadrigal Pharmaceuticals2.90Moderate Buy$377.4065.28% UpsideCurrent Analyst RatingsLatest INSM, ENTA, DCPH, MDGL, and AIMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024INSMInsmedBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$37.00 ➝ $40.004/1/2024INSMInsmedWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$55.003/20/2024DCPHDeciphera PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$14.00 ➝ $16.003/20/2024MDGLMadrigal PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$325.00 ➝ $405.003/15/2024MDGLMadrigal PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$405.00 ➝ $425.003/15/2024MDGLMadrigal PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$338.00 ➝ $377.003/15/2024MDGLMadrigal PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$320.00 ➝ $375.003/15/2024MDGLMadrigal PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$351.00 ➝ $397.003/15/2024MDGLMadrigal PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$382.00 ➝ $389.003/15/2024MDGLMadrigal PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$349.00 ➝ $390.003/15/2024MDGLMadrigal PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$337.00 ➝ $410.00(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMTAimmune TherapeuticsN/AN/AN/AN/A$1.66 per shareN/ADCPHDeciphera Pharmaceuticals$163.36M7.28N/AN/A$4.38 per share3.36ENTAEnanta Pharmaceuticals$79.20M3.74N/AN/A$10.29 per share1.36INSMInsmed$305.21M12.74N/AN/A($2.32) per share-11.28MDGLMadrigal PharmaceuticalsN/AN/AN/AN/A$20.53 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMTAimmune Therapeutics-$248.50M-$3.97N/AN/AN/AN/A-164.99%-89.50%N/ADCPHDeciphera Pharmaceuticals-$194.94M-$2.29N/AN/AN/A-119.33%-49.44%-38.41%5/1/2024 (Estimated)ENTAEnanta Pharmaceuticals-$133.82M-$6.56N/AN/AN/A-187.77%-60.38%-32.29%5/13/2024 (Estimated)INSMInsmed-$749.57M-$5.34N/AN/AN/A-245.59%N/A-53.34%5/2/2024 (Estimated)MDGLMadrigal Pharmaceuticals-$373.63M-$19.94N/AN/AN/AN/A-219.39%-98.75%5/14/2024 (Estimated)Latest INSM, ENTA, DCPH, MDGL, and AIMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/28/2024Q4 2023MDGLMadrigal Pharmaceuticals-$5.26-$5.68-$0.42-$5.68N/AN/A2/22/202412/31/2023INSMInsmed-$1.13-$1.28-$0.15-$1.28$82.15 million$83.70 million 2/7/2024Q1 2024ENTAEnanta Pharmaceuticals-$1.18-$1.58-$0.40-$1.58$22.74 million$18.00 million2/6/2024Q4 2023DCPHDeciphera Pharmaceuticals-$0.58-$0.54+$0.04-$0.54$45.93 million$48.30 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMTAimmune TherapeuticsN/AN/AN/AN/AN/ADCPHDeciphera PharmaceuticalsN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMTAimmune Therapeutics0.737.537.40DCPHDeciphera PharmaceuticalsN/A3.803.59ENTAEnanta PharmaceuticalsN/A6.256.25INSMInsmedN/A4.123.75MDGLMadrigal Pharmaceuticals0.285.385.38OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMTAimmune Therapeutics74.47%DCPHDeciphera Pharmaceuticals70.96%ENTAEnanta Pharmaceuticals94.99%INSMInsmedN/AMDGLMadrigal Pharmaceuticals98.50%Insider OwnershipCompanyInsider OwnershipAIMTAimmune Therapeutics13.75%DCPHDeciphera Pharmaceuticals4.43%ENTAEnanta Pharmaceuticals13.64%INSMInsmed4.60%MDGLMadrigal Pharmaceuticals23.92%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAIMTAimmune Therapeutics22865.45 millionN/AOptionableDCPHDeciphera Pharmaceuticals35580.80 million77.22 millionOptionableENTAEnanta Pharmaceuticals14521.16 million18.27 millionOptionableINSMInsmed373148.55 million141.72 millionOptionableMDGLMadrigal Pharmaceuticals37619.90 million15.14 millionOptionableINSM, ENTA, DCPH, MDGL, and AIMT HeadlinesSourceHeadlineMadrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price Down 3.3%marketbeat.com - April 17 at 12:20 PMMadrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - April 16 at 4:05 PM7 Stocks Analysts Are Loving Right Now (And You Should Too): April 2024investorplace.com - April 15 at 7:52 AM211,488 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Purchased by AlpInvest Partners B.V.marketbeat.com - April 14 at 8:45 PMRebecca Taub Sells 2,676 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stockamericanbankingnews.com - April 12 at 5:52 AMPaul A. Friedman Sells 26,270 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stockamericanbankingnews.com - April 12 at 4:16 AMMadrigal Pharmaceuticals (NASDAQ:MDGL) Stock Rating Upgraded by StockNews.comamericanbankingnews.com - April 12 at 2:52 AMMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Rebecca Taub Sells 2,676 Sharesinsidertrades.com - April 11 at 6:37 AMMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Paul A. Friedman Sells 26,270 Shares of Stockinsidertrades.com - April 11 at 6:16 AMMadrigal Pharmaceuticals Launches Rezdiffra, a Pioneer in NASH Treatmentmsn.com - April 10 at 10:34 PM2 Under-the-Radar Growth Stocks to Considermsn.com - April 10 at 12:33 PM2 Under-the-Radar Growth Stocks to Considerfool.com - April 10 at 10:15 AMMoody Aldrich Partners LLC Sells 4,356 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)marketbeat.com - April 10 at 8:54 AMFirst ever MASH drug primed for big impact in USAthepharmaletter.com - April 9 at 4:17 PMMadrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosisfinance.yahoo.com - April 9 at 8:42 AMJames M. Daly Sells 32,489 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stockinsidertrades.com - April 9 at 4:22 AMMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells $4,545,781.60 in Stockamericanbankingnews.com - April 8 at 4:56 AMInsider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Sells 27,845 Shares of Stockamericanbankingnews.com - April 8 at 4:20 AMInsider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Sells 27,506 Shares of Stockamericanbankingnews.com - April 8 at 4:20 AMMadrigal Pharmaceuticals, Inc.cnn.com - April 7 at 1:19 AMMadrigal Pharmaceuticals Awards Equity to New Employees as Inducementmsn.com - April 6 at 8:18 PMInsider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells 18,710 Shares of Stockinsidertrades.com - April 6 at 7:30 AMMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Paul A. Friedman Sells 18,710 Sharesmarketbeat.com - April 5 at 9:06 PMBetter Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeuticsfool.com - April 5 at 7:15 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines5 Semiconductor Giants: Navigating the Recent PullbackApril 12, 2024 9:10 AMView 5 Semiconductor Giants: Navigating the Recent PullbackWayfair: Strengthening Fundamentals or Just a Short Squeeze? April 2, 2024 7:45 AMView Wayfair: Strengthening Fundamentals or Just a Short Squeeze? 3 Real Estate Stocks to Buy on Commission CutsMarch 20, 2024 6:15 AMView 3 Real Estate Stocks to Buy on Commission CutsPayPal’s User Decline Won’t Stop Its Double-Digit UpsideApril 16, 2024 9:08 AMView PayPal’s User Decline Won’t Stop Its Double-Digit UpsideTaylor Morrison: A Home Building Stock You Can Buy at a DiscountApril 11, 2024 7:00 AMView Taylor Morrison: A Home Building Stock You Can Buy at a DiscountAll Headlines Company DescriptionsAimmune TherapeuticsNASDAQ:AIMTAimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.Deciphera PharmaceuticalsNASDAQ:DCPHDeciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.Enanta PharmaceuticalsNASDAQ:ENTAEnanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.InsmedNASDAQ:INSMInsmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Madrigal PharmaceuticalsNASDAQ:MDGLMadrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.